Cytokine Regulation of Dendritic Cell Development
树突状细胞发育的细胞因子调节
基本信息
- 批准号:7497558
- 负责人:
- 金额:$ 18.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-21 至 2011-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAntigen PresentationB-LymphocytesBone MarrowCell LineageCell SurvivalCellsClinicalCoculture TechniquesCytokine SignalingDendritic CellsDevelopmentDiseaseDrug or chemical Tissue DistributionFamilyFamily memberFeedbackFrequenciesGene ExpressionGenesGoalsGranulocyte-Macrophage Colony-Stimulating FactorGrowthGrowth and Development functionHematopoieticHematopoietic SystemHematopoietic stem cellsImmune responseImmunityInfectionInflammationInterferon Type IInterferonsInterleukin-12LigandsLymphoidMHC Class II GenesMacrophage Colony-Stimulating Factor ReceptorMeasuresMediatingMediator of activation proteinMethodsMolecularMyelogenousNumbersOrganPathway interactionsPattern recognition receptorPhenotypePlayPrincipal InvestigatorProductionRegulationRegulatory PathwayRelative (related person)RoleSTAT proteinSTAT3 geneSTAT5A geneSignal PathwaySignal TransductionSignaling ProteinStagingStem cellsSurfaceT-LymphocyteTestingTherapeuticToll-like receptorsUp-RegulationVirus Diseasesantimicrobialbasecytokinein vivomicrobial hostpathogenperipheral bloodprogenitorprogramsreceptorreceptor expressionresponsetranscription factor
项目摘要
DESCRIPTION (provided by applicant): Dendritic cells (DCs) provide a critical connection between the innate and adaptive immune responses by receiving signals from pathogens via pattern recognition receptors and transmitting signals that activate na¿ve T cells, NK and B cells. Several DC subsets exist, which display important differences in function. Plasmacytoid dendritic cell precursors (pDCs) are professional type I interferon-producing cells, while conventional or myeloid dendritic cells (mDCs) demonstrate potent antigen presentation function. The pathways that control development of these DC subsets are unknown. Once elucidated, this information may provide methods to control or redirect immune responses during infection, disease or for therapeutic applications. The goal of this project is to understand the molecular regulation of pDC and mDC development by cytokines. Maturation of pDCs is critically dependent on Flt3 ligand (Flt3L) and its downstream signaling protein STAT3. Flt3L-dependent pDC development is severely inhibited by granulocyte-macrophage colony- stimulating factor (GM-CSF), which promotes mDC formation at the expense of pDCs. The suppressive activity of GM-CSF on pDC development operates at the progenitor pDC (pro-pDC) stage and requires the transcription factor STAT5. These findings led to the hypothesis that GM-CSF-activated STAT5 stimulates a transcriptional program that represses Flt3-dependent STAT3 signaling and/or expression of critical lineage- specification factors, thus abrogating pDC development. Two aims are proposed to test this hypothesis. In Aim 1, the role of GM-CSF and STAT5 in modulating Flt3 function in pDCs and pro-pDCs will be determined. Cellular responses to GM-CSF will be examined by measuring the survival, growth and absolute production of pDCs and mDCs from wild-type or STAT5-deficient pro-pDCs in Flt3L cultures containing or lacking GM-CSF. Molecular mechanisms of GM-CSF will be evaluated by examining Flt3 and GM-CSF receptor expression, Flt3/STAT3 signal transduction, and expression of SOCS family negative regulators in wild type and STAT5- deficient cells. In Aim 2, the effect of GM-CSF signaling and STAT5 activity on the pDC and mDC transcriptional regulatory networks will be examined. Candidate DC and STAT target gene expression will be measured during development of wild type, STAT5- and STAT3-deficient pDCs and mDCs. This project will reveal regulatory pathways of DC development by cytokines.
描述(由申请人提供):树突状细胞(dc)通过模式识别受体接收来自病原体的信号并传递激活na - T细胞,NK细胞和B细胞的信号,在先天和适应性免疫反应之间提供关键连接。存在几个DC子集,它们在功能上显示出重要的差异。浆细胞样树突状细胞前体(pDCs)是专业的I型干扰素产生细胞,而传统或髓样树突状细胞(mDCs)表现出强大的抗原呈递功能。控制这些DC亚群发展的途径尚不清楚。一旦得到阐明,这一信息可能为控制或重新定向感染、疾病期间的免疫反应或治疗应用提供方法。本项目的目的是了解细胞因子对pDC和mDC发育的分子调控。pDCs的成熟严重依赖于Flt3配体(Flt3L)及其下游信号蛋白STAT3。flt3l依赖性pDC的发育受到粒细胞-巨噬细胞集落刺激因子(GM-CSF)的严重抑制,后者以牺牲pDC为代价促进mDC的形成。GM-CSF对pDC发育的抑制作用发生在pDC祖细胞(pro-pDC)阶段,需要转录因子STAT5的参与。这些发现导致假设gm - csf激活的STAT5刺激转录程序,抑制flt3依赖的STAT3信号和/或关键谱系特异性因子的表达,从而消除pDC的发展。为了验证这一假设,提出了两个目标。在Aim 1中,将确定GM-CSF和STAT5在pDCs和pro-pDCs中调节Flt3功能的作用。在含有或缺乏GM-CSF的Flt3L培养中,将通过测量野生型或缺乏stat5的前pDCs的存活、生长和pDCs和mDCs的绝对产量来检测细胞对GM-CSF的反应。通过检测野生型和STAT5缺陷细胞中Flt3和GM-CSF受体的表达、Flt3/STAT3信号转导以及SOCS家族阴性调节因子的表达,将评估GM-CSF的分子机制。在Aim 2中,将研究GM-CSF信号传导和STAT5活性对pDC和mDC转录调控网络的影响。候选DC和STAT靶基因的表达将在野生型、STAT5-和stat3缺乏的pDCs和mDCs的发育过程中进行测量。本项目将揭示细胞因子对DC发育的调控途径。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
miR-22 controls Irf8 mRNA abundance and murine dendritic cell development.
- DOI:10.1371/journal.pone.0052341
- 发表时间:2012
- 期刊:
- 影响因子:3.7
- 作者:Li HS;Greeley N;Sugimoto N;Liu YJ;Watowich SS
- 通讯作者:Watowich SS
Innate immune regulation by STAT-mediated transcriptional mechanisms.
- DOI:10.1111/imr.12198
- 发表时间:2014-09
- 期刊:
- 影响因子:8.7
- 作者:Li HS;Watowich SS
- 通讯作者:Watowich SS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stephanie S Watowich其他文献
UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies
- DOI:
10.1182/blood-2023-187438 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Chiharu Ishikawa;Laura Barreyro;Avery Sampson;Kathleen Hueneman;Kwangmin Choi;Lyndsey C. Bolanos;Andrew Volk;Stephanie S Watowich;Kenneth Greis;Daniel T. Starczynowski - 通讯作者:
Daniel T. Starczynowski
STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions
- DOI:
10.1182/blood-2022-170250 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Bhakti Patel;Yifan Zhou;Rachel L Babcock;Feiyang Ma;Yusra B Medik;Laura M Kahn;Josue E Pineda;Elizabeth Park;Karen Clise-Dwyer;Simona Colla;Stephanie S Watowich - 通讯作者:
Stephanie S Watowich
Stephanie S Watowich的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stephanie S Watowich', 18)}}的其他基金
Regulation and function of nonlymphoid organ CD103+ dendritic cells
非淋巴器官CD103树突状细胞的调节和功能
- 批准号:
10469028 - 财政年份:2021
- 资助金额:
$ 18.39万 - 项目类别:
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity
定义 STAT3 抗炎活性介导的造血细胞保护反应
- 批准号:
9906160 - 财政年份:2018
- 资助金额:
$ 18.39万 - 项目类别:
Defining Protective Responses in Hematopoietic Cells Mediated by STAT3 Anti-Inflammatory Activity
定义 STAT3 抗炎活性介导的造血细胞保护反应
- 批准号:
10393508 - 财政年份:2018
- 资助金额:
$ 18.39万 - 项目类别:
Regulation and function of nonlymphoid organ CD103 dendritic cells
非淋巴器官CD103树突状细胞的调节和功能
- 批准号:
8832406 - 财政年份:2015
- 资助金额:
$ 18.39万 - 项目类别:
Pathways regulating plasmacytoid dendritic cells in Peyers Patches
派氏斑中浆细胞样树突状细胞的调节途径
- 批准号:
8233828 - 财政年份:2012
- 资助金额:
$ 18.39万 - 项目类别:
Pathways regulating plasmacytoid dendritic cells in Peyers Patches
派氏斑中浆细胞样树突状细胞的调节途径
- 批准号:
8432435 - 财政年份:2012
- 资助金额:
$ 18.39万 - 项目类别:
Cytokine Regulation of Dendritic Cell Development
树突状细胞发育的细胞因子调节
- 批准号:
7240401 - 财政年份:2007
- 资助金额:
$ 18.39万 - 项目类别:
MOLECULAR MECHANISMS CYTOKINE RECEPTOR SIGNALING
细胞因子受体信号转导的分子机制
- 批准号:
6173091 - 财政年份:1998
- 资助金额:
$ 18.39万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别: